


	MEDICAL PO	LICY STATE	MENT			
MEDICAL POLICY STATEMENT OHIO MEDICAID						
Policy Name		Policy Number	Date Effective			
	nt Field Devices for na Multiforme	MM-1224	11/15/2021-10/31/2022			
Policy Type						
MEDICAL	Administrative	Pharmacy	Reimbursement			
health care services or sup without which the patient of a body organ or part, or sig area, are the lowest cost a	oplies that are proper and neces can be expected to suffer prolon gnificant pain and discomfort. T Iternative, and are not provided	ssary for the diagnosis or treatr ged, increased or new morbidit hese services meet the standa d mainly for the convenience of	nclude, but are not limited to, those ment of disease, illness, or injury and y, impairment of function, dysfunction of urds of good medical practice in the local the member or provider. Medically cuments, Medical Policy Statements,			

## Table of Contents

Α.	Subject	 2
	Background	
C.	Definitions	2
	Policy	
	Conditions of Coverage	
	Related Polices/Rules	
	Review/Revision History	
	References	



Tumor Treatment Field Devices for Glioblastoma Multiforme (GBM)

## B. Background

Glioblastoma Multiforme is the most common central nervous system malignancy of the brain in adults, with an average onset age between 55 to 60 years. The incidence rate between 2010 and 2014 was 29.2 per 100,000 in adults, and 5.81 per 100,000 in children. Management of the disease follows a combined-modality approach, including: adjuvant postoperative radiation therapy and adjuvant chemotherapy following initial surgery. Surgery remains the mainstay of treatment in order to remove as much tumor as possible while preserving surrounding brain tissue required for normal brain function. Despite tumor debulking measures, glioblastoma tumors infiltrate surrounding tissues creating little success for removal of the entire tumor (AANS, 2020). Glioblastoma has a high rate of recurrence and poor overall survival rate even with optimum therapy treatments. Most patients live one - two years after initial diagnosis.

Tumor treating field devices (TTF) are the novel method of cancer treatment involving emitting alternating electric fields to disrupt the rapid cell division exhibited by cancer cells. This treatment first became available in 2011 to treat recurrent glioblastoma. TTF is considered safe with no systemic toxicity observed and only mild to moderate side effects (reported in 1-2% of patients) involving the skin beneath transducer arrays. Patients are required to wear the device at least eighteen hours a day for effectiveness and minimum treatment duration is four weeks. Randomized trial results suggest the device improves overall survival when combined with monthly temozolomide in patients with newly diagnosed glioblastoma in the post radiation setting.

## C. Definitions

- Medically Necessary "The evaluation of health care services to determine if they are medically appropriate and necessary to meet basic health needs; consistent with the diagnosis or condition and rendered in a cost-effective manner; and consistent with national medical practice guidelines regarding type, frequency, and duration of treatment."
- Tumor Treatment Fields (TTF) -





